Identification of potential differentially methylated gene-related biomarkers in endometriosis
Abstract
Aim: To identify epigenetic alterations of differentially expressed genes and screen out targeted therapeutic drugs in endometriosis. Methods: Based on the Gene Expression Omnibus database and a series of biological information analysis tools, supplemented by validation of clinical samples, aberrant DNA methylation-driven genes and their functions were explored, as well as possible targeted drugs. Results: This study screened out a range of DNA methylation-driven genes that were associated with powerful properties and corresponding pathways. Among them, BDNF and CCL2 were key genes in the development of endometriosis. Four chemical agents have been flagged as potential treatments for endometriosis. Conclusion: These candidate genes and small-molecule agents may be further explored as potential targets and drugs for endometriosis diagnosis and therapy, respectively.
Plain language summary
What is the significance of studying endometriosis? Endometriosis is a common gynecological benign disease affecting an estimated 5–10% of women in their reproductive years. Women with endometriosis suffer from chronic pelvic pain, dyspareunia and dysmenorrhea, and some patients face the possibility of infertility. What were the results of this study? The authors explored a number of key genes that may contribute to the etiology and pathogenesis of endometriosis, discussed the reasons for the changes in the expression levels of these hub genes and then screened for a number of effective small-molecule chemical drugs that may act on endometriosis. What do the results of this study mean? The authors carried out research from the three aspects of etiology, diagnosis and treatment of endometriosis. First, it demonstrated that endometriosis patients did have some differentially expressed genes compared with controls, and then in the analysis of these abnormally expressed genes, it was found that DNA methylation may play an essential role. This is a more meaningful hint, whether the occurrence of endometriosis can be suppressed by targeting methylation modification and then affecting the expression of key genes. In addition, the different severity of endometriosis will also have varying degrees of impact on patients' quality of life. These results are also a good indicator of the severity of endometriosis. Therefore, early detection and timely treatment are guidelines for the treatment of endometriosis. Finally, some of the chemical agents identified to target the cause of endometriosis are expected to become new treatments for endometriosis, supported by the results of follow-up studies, which will lead to more accurate treatments for patients with fewer side effects than existing treatments.
Papers of special note have been highlighted as: •• of considerable interest
References
- 1. Neuropeptide S receptor 1 is a nonhormonal treatment target in endometriosis. Sci. Transl. Med. 13(608), eabd6469 (2021).
- 2. . Pathogenesis and pathophysiology of endometriosis. Fertil. Steril. 98(3), 511–519 (2012). •• This is a review on the etiology and pathophysiology of endometriosis and the article elaborates on the existing hypotheses and theories of endometriosis.
- 3. . Endometriosis is a chronic systemic disease: clinical challenges and novel innovations. Lancet 397(10276), 839–852 (2021). •• In this review, they discuss the latest understanding of endometriosis as a systemic disease with multiple manifestations outside the parameters of classic gynecological disease.
- 4. . The endometrial immune environment of women with endometriosis. Hum. Reprod. Update 25(5), 564–591 (2019).
- 5. . Retrograde menstruation in healthy women and in patients with endometriosis. Obstet. Gynecol. 64(2), 151–154 (1984).
- 6. . The origin and pathogenesis of endometriosis. Annu. Rev. Pathol. 15, 71–95 (2020).
- 7. . Clinical practice. Endometriosis. N. Engl. J. Med. 362(25), 2389–2398 (2010).
- 8. . Endometriosis and infertility: insights into the causal link and management strategies. Best Pract. Res. Clin. Obstet. Gynaecol. 51, 25–33 (2018).
- 9. Usefulness and limits of CA-125 in diagnosis of endometriosis without associated ovarian endometriomas. Hum. Reprod. 20(7), 1999–2003 (2005).
- 10. . Genetics of endometriosis. Clin. Obstet. Gynecol. 60(3), 531–538 (2017).
- 11. Challenges in endometriosis miRNA studies – from tissue heterogeneity to disease specific miRNAs. Biochim. Biophys. Acta Mol. Basis Dis. 1863(9), 2282–2292 (2017). •• This review focuses on the results of published miRNA studies in endometriosis to reveal the potential impact of tissue heterogeneity on the discovery of disease-specific miRNA alterations in endometriosis. Additionally, functional studies exploring the role of miRNAs involved in endometriosis are discussed.
- 12. . Emerging promise of epigenetics and DNA methylation for the diagnosis and management of women's cancers. Epigenomics 2(1), 9–38 (2010). •• This article provides an overview of technological development, current markers of risk prediction, early detection, diagnosis, prognosis and response to treatment and highlights the progression of epigenetic therapies.
- 13. . Biological embedding of early-life exposures and disease risk in humans: a role for DNA methylation. Eur. J. Clin. Invest. 45(3), 303–332 (2015).
- 14. . Methylation matters. J. Med. Genet. 38(5), 285–303 (2001).
- 15. . Identification of key differentially methylated/expressed genes and pathways for ovarian endometriosis by bioinformatics analysis. Reprod. Sci. 29(5), 1630–1643 (2022).
- 16. . Screening differentially expressed genes between endometriosis and ovarian cancer to find new biomarkers for endometriosis. Ann. Med. 53(1), 1377–1389 (2021).
- 17. Aberrant DNA methylation status of endometriosis: epigenetics as the pathogenesis, biomarker and therapeutic target. J. Obstet. Gynaecol. Res. 37(7), 683–695 (2011).
- 18. . The Gene Expression Omnibus database. Methods Mol. Biol. 1418, 93–110 (2016). •• The Gene Expression Omnibus database is an international public repository that archives and freely distributes high-throughput gene expression and other functional genomics datasets. This article includes detailed descriptions of methods to query and download Gene Expression Omnibus data and use the analysis and visualization tools.
- 19. Identification of potential core genes in triple negative breast cancer using bioinformatics analysis. OncoTargets Ther. 11, 4105–4112 (2018).
- 20. Epigenetic alternations of microRNAs and DNA methylation contribute to gestational diabetes mellitus. J. Cell. Mol. Med. 24(23), 13899–13912 (2020).
- 21. . Aberrantly methylated-differentially expressed genes and pathways in colorectal cancer. Cancer Cell Int. 17, 75 (2017).
- 22. Identification of aberrantly methylated differentially expressed genes and associated pathways in endometrial cancer using integrated bioinformatic analysis. Cancer Med. 9(10), 3522–3536 (2020).
- 23. . STITCH 5: augmenting protein–chemical interaction networks with tissue and affinity data. Nucleic Acids Res. 44(D1), D380–D384 (2016). •• STITCH database is usually used to explore the relationship between hub genes and drugs, and each compound–protein interaction relation in the STITCH database corresponds to a score indicating its interaction probability or binding affinity and provides the compounds that are similar to the target drug and their similarity scores.
- 24. . Potential targets and action mechanism of gastrodin in the treatment of attention-deficit/hyperactivity disorder: bioinformatics and network pharmacology analysis. Evid. Based Complement. Alternat. Med. 2022, 3607053 (2022).
- 25. Defining the genetic profile of endometriosis. Exp. Ther. Med. 17(5), 3267–3281 (2019).
- 26. . Genetic, epigenetic, and steroidogenic modulation mechanisms in endometriosis. J. Clin. Med. 9(5), 1309 (2020).
- 27. Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer. Lab. Invest. 90(3), 414–425 (2010).
- 28. Aberrant methylation and decreased expression of the TGF-β/Smad target gene FBXO32 in esophageal squamous cell carcinoma. Cancer 120(16), 2412–2423 (2014).
- 29. . miR-19a-3p functions as an oncogene by regulating FBXO32 expression in multiple myeloma. Balkan Med. J. 38(1), 43–49 (2021).
- 30. A panel of differentially methylated regions enable prognosis prediction for colorectal cancer. Genomics 113(5), 3285–3293 (2021).
- 31. . Over-expression of the miRNA cluster at chromosome 14q32 in the alcoholic brain correlates with suppression of predicted target mRNA required for oligodendrocyte proliferation. Gene 526(2), 356–363 (2013).
- 32. . Correlations between gastric cancer family history and ROBO2 and RASSF2A gene methylations. J. Cancer Res. Ther. 12(2), 597–600 (2016).
- 33. MicroRNA-338 attenuates cortical neuronal outgrowth by modulating the expression of axon guidance genes. Mol. Neurobiol. 54(5), 3439–3452 (2017).
- 34. . A novel epigenetic regulation of circFoxp1 on Foxp1 in colon cancer cells. Cell. Death Dis. 11(9), 782 (2020).
- 35. . Adhesion of menstrual endometrium to extracellular matrix: the possible role of integrin alpha(6)beta(1) and laminin interaction. Mol. Hum. Reprod. 6(2), 170–177 (2000).
- 36. . Extracellular matrix-dependent regulation of Fas ligand expression in human endometrial stromal cells. Biol. Reprod. 66(1), 1–5 (2002).
- 37. . lncRNA AFAP1-AS1 regulates proliferation and apoptosis of endometriosis through activating STAT3/TGF-β/Smad signaling via miR-424-5p. J. Obstet. Gynaecol. Res. 47(7), 2394–2405 (2021).
- 38. . miR-96-5p regulated TGF-β/SMAD signaling pathway and suppressed endometrial cell viability and migration via targeting TGFBR1. Cell Cycle 19(14), 1740–1753 (2020).
- 39. . The inhibition of bone morphogenetic protein 1 attenuates endometriosis lesions in vivo and in vitro. Arch. Gynecol. Obstet. 302(2), 415–422 (2020).
- 40. . Genome-wide DNA methylation profiling in ectopic and eutopic of endometrial tissues. J. Assist. Reprod. Genet. 36(8), 1743–1752 (2019).
- 41. PI3K/AKT pathway is altered in the endometriosis patient's endometrium and presents differences according to severity stage. Gynecol. Endocrinol. 36(5), 436–440 (2020).
- 42. Inhibiting DNA methylation improves survival in severe sepsis by regulating NF-κB pathway. Front. Immunol. 11, 1360 (2020).
- 43. SMYD2-mediated TRAF2 methylation promotes the NF-κB signaling pathways in inflammatory diseases. Clin. Transl. Med. 11(11), e591 (2021).
- 44. Curcumin attenuates proangiogenic and proinflammatory factors in human eutopic endometrial stromal cells through the NF-κB signaling pathway. J. Cell. Physiol. 234(5), 6298–6312 (2019).
- 45. Chemokine CCL2 enhances survival and invasiveness of endometrial stromal cells in an autocrine manner by activating Akt and MAPK/Erk1/2 signal pathway. Fertil. Steril. 97(4), 919–929 (2012).
- 46. BDNF and TrKB expression levels in patients with endometriosis and their associations with dysmenorrhoea. J. Ovarian Res. 15(1), 35 (2022).
- 47. BDNF promoter methylation associated with suicidal ideation in patients with breast cancer. Int. J. Psychiatry Med. 49(1), 75–94 (2015).
- 48. . Proteomic identification of neurotrophins in the eutopic endometrium of women with endometriosis. Fertil. Steril. 98(3), 713–719 (2012).
- 49. . Farnesoid X receptor agonist GW4064 inhibits aromatase and ERβ expression in human endometriotic stromal cells. Reprod. Sci. 26(8), 1111–1120 (2019).
- 50. Betulinic acid inhibits endometriosis through suppression of estrogen receptor β signaling pathway. Front. Endocrinol. (Lausanne) 11, 604648 (2020).
- 51. . Advances in the management of endometriosis in the adolescent. Curr. Opin. Obstet. Gynecol. 30(5), 326–330 (2018).
- 52. . Seven days of statin treatment improves nitric-oxide mediated endothelial-dependent cutaneous microvascular function in women with endometriosis. Microvasc. Res. 144, 104421 (2022).
- 53. . Peroxisome proliferator-activated receptor-gamma ligand reduced tumor necrosis factor-alpha-induced interleukin-8 production and growth in endometriotic stromal cells. Fertil. Steril. 89(2), 311–317 (2008).
- 54. Development and prevention of postsurgical adhesions in a chimeric mouse model of experimental endometriosis. Fertil. Steril. 95(4), 1295–301.e1 (2011).